Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study.
A four-drug adjuvant chemotherapy regimen (CONPADRI-I) was utilized in the primary treatment of 18 children with osteogenic sarcoma. All patients had surgical amputation for the primary lesion. The children then received cyclophosphamide, vincristine, melphalan, and adriamycin in defined combinations intermittently over a 72-week period. Of the 18 patients, 10 (55%) remain free of disease 24 months or longer from time of amputation.
D000293:Adolescent; D000328:Adult; D000671:Amputation, Surgical; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy* / Q000601:surgery; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan